Intralytix, Inc.   Report issue

For profit Phase 2
Founded: Baltimore MD United States (1987)

Organization Overview

First Clinical Trial
2019
NCT03808103
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Intralytix, Inc.